Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	5.46B
Revenue (ttm)	972.89M
Net Income (ttm)	648.69M
Shares Out	n/a
EPS (ttm)	0.84
PE Ratio	8.41
Forward PE	n/a
Dividend	0.23 (8.96%)
Ex-Dividend Date	Jun 25, 2025

Volume	614,500
Average Volume	209,160
Open	2.750
Previous Close	2.550
Day's Range	2.750 - 2.920
52-Week Range	1.990 - 3.130
Beta	n/a
RSI	58.23
Earnings Date	Oct 31, 2025

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2024, SGX:T14's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial numbers in CNY